Zevra Therapeutics, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Zevra Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $428.00K, a 3.63% increase year-over-year.
- Zevra Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $413.00K, a 2.59% decline year-over-year.
- Zevra Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-03-31 was $63.00K, a 11.27% decline year-over-year.
- Zevra Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-09-30 was $92.00K.
- Zevra Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $615.00K, a 41.87% decline from fiscal 2024.
- Zevra Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $1.06M, a 385.32% increase from fiscal 2023.
- Zevra Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $218.00K, a 32.72% decline from fiscal 2022.
- Zevra Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $324.00K.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $428.00K 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $615.00K 10-K · filed 2026-03-09 | |
| 2025-06-30 | $413.00K 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $63.00K 10-Q · filed 2026-05-06 | |
| 2024-12-31 | $1.06M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $92.00K 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $424.00K 10-Q · filed 2025-11-05 | |
| 2024-03-31 | $71.00K 10-Q · filed 2025-05-13 | |
| 2023-12-31 | $218.00K 10-K · filed 2025-03-12 | |
| 2023-06-30 | $165.00K 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $324.00K 10-K · filed 2024-04-01 | |
| 2022-06-30 | $216.00K 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |